CNS Pharmaceuticals, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
NV
Business Address
2100 WEST LOOP SOUTH, HOUSTON, TX, 77027
Mailing Address
2100 WEST LOOP SOUTH, HOUSTON, TX, 77027
Phone
1-800-946-9185
Fiscal Year End
1231
EIN
822318545
Financial Overview
FY2025
-$14.86M
Net Income
$4.10M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 3 Initial insider ownership report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 3 Initial insider ownership report | March 4, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| 8-K Current report of material events | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| 3 Initial insider ownership report | January 2, 2026 | View on SEC |
Annual Reports
10-K
March 31, 2026
- Strategic pivot to a 'buy-to-build' model to acquire near-approval assets.
- New leadership under CEO Rami Levin focused on corporate restructuring.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.